Quick Answers: GLP-1 Eligibility Questions
Common questions about qualifying for GLP-1 medications — answered based on FDA-approved prescribing information and published eligibility criteria.
Qualifying for a GLP-1 medication depends on the specific drug, its FDA-approved indication, your BMI, medical history, other medications you take, contraindications, and a licensed clinician's review. Wegovy and Zepbound are approved for chronic weight management in eligible adults. Ozempic and Mounjaro are approved for type 2 diabetes — different eligibility criteria apply. No website or quiz can determine your eligibility; that requires an individualized medical evaluation by a licensed clinician.
For FDA-approved weight-management medications, Wegovy (semaglutide) and Zepbound (tirzepatide) are indicated for adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia. Ozempic is approved for type 2 diabetes management — its eligibility criteria differ. Reaching a BMI threshold is a starting point, not a guarantee. A licensed clinician must assess your full medical history before prescribing.
No. Ozempic (semaglutide) is FDA-approved for type 2 diabetes management, not as a weight-loss medication. Wegovy — a different semaglutide formulation at a different approved dose — is the FDA-approved option for chronic weight management. If a clinician prescribes Ozempic off-label for weight management, that is an individualized clinical decision. This page cannot advise whether an off-label use is appropriate for your situation.
Licensed online GLP-1 programs begin with a health intake form covering your height, weight, BMI, medical history, current medications, and health goals. A licensed clinician reviews your information and determines whether a GLP-1 medication is medically appropriate. If it is, the clinician writes a prescription filled by a licensed pharmacy. Not every applicant will receive a prescription — medical screening is required and medical appropriateness must be established. See how online GLP-1 prescriptions work for more detail.
Insurance coverage varies significantly by insurer, plan type, employer, state, and specific medication. Some plans cover Wegovy or Zepbound for weight management; others exclude them or require prior authorization. Ozempic and Mounjaro coverage for type 2 diabetes is more common but still plan-specific. Medical eligibility and insurance coverage are entirely separate issues — clinically qualifying for a medication does not mean your plan will cover it. See our GLP-1 cost guide and insurance coverage page for more detail.
Prescription GLP-1 medications obtained with a valid prescription may qualify as reimbursable medical expenses under a Health Savings Account (HSA) or Flexible Spending Account (FSA). However, eligibility depends on your specific plan, account type, and how the expense is categorized. Consult your plan administrator or a tax professional for guidance specific to your situation. This page does not provide tax or financial advice.
If a licensed clinician determines you do not qualify, do not attempt to misrepresent your health information or find ways around the medical screening process. A clinician can discuss other evidence-based treatment options, lifestyle support programs, risk factors, or whether your situation may change over time. Bypassing legitimate medical screening creates health risks and may be fraudulent.
Eligibility Depends on the Medication
GLP-1 medications are not interchangeable — they have different FDA-approved indications, different eligibility criteria, and different risk profiles. Whether you may qualify depends heavily on which specific drug is being considered, not just whether you've heard of GLP-1 medications in general.
| Medication | Active Ingredient | FDA Indication | General BMI Threshold | Key Notes |
|---|---|---|---|---|
| Wegovy semaglutide 2.4 mg |
Semaglutide | Weight Management | BMI ≥ 30, or ≥ 27 with weight-related comorbidity | FDA-approved for chronic weight management in adults and adolescents (12+). Requires full medical history review. Wegovy online |
| Zepbound tirzepatide |
Tirzepatide | Weight Management | BMI ≥ 30, or ≥ 27 with weight-related comorbidity | FDA-approved for chronic weight management. Dual GLP-1/GIP mechanism. Requires full medical screening. Zepbound online |
| Ozempic semaglutide 0.5–2 mg |
Semaglutide | Type 2 Diabetes | Type 2 diabetes diagnosis; BMI criteria differ | FDA-approved for type 2 diabetes, not weight loss. Off-label use for weight management requires individualized clinical judgment. Not equivalent to Wegovy. Learn more |
| Mounjaro tirzepatide |
Tirzepatide | Type 2 Diabetes | Type 2 diabetes diagnosis; BMI criteria differ | FDA-approved for type 2 diabetes, not weight loss. Not equivalent to Zepbound for weight-management eligibility. Off-label use requires individualized review. Learn more |
Table reflects general FDA-approved indication context. Individual eligibility requires a licensed clinician's full medical evaluation. See official Wegovy prescribing information and Zepbound prescribing information for complete indication language.
Common BMI Criteria for Weight-Management GLP-1 Medications
For FDA-approved weight-management GLP-1 medications — specifically Wegovy (semaglutide) and Zepbound (tirzepatide) — prescribing information identifies BMI thresholds as part of the indication. Understanding these thresholds helps frame what a clinician may consider, but meeting a BMI threshold alone does not automatically qualify you for a prescription.
BMI ≥ 30 (Obesity)
Adults with a BMI of 30 or greater fall within the obesity classification used in FDA-approved weight-management indications for Wegovy and Zepbound. This is a primary threshold, subject to full medical history review and contraindication screening by a licensed clinician.
BMI ≥ 27 with Comorbidity
Adults with a BMI of 27 or greater may meet the indication threshold if they also have at least one weight-related health condition — such as hypertension, type 2 diabetes, or dyslipidemia. The specific comorbidity and clinical documentation both matter for evaluation.
BMI Alone Is Not Enough
Even if your BMI meets the threshold, your full medical history, current medications, contraindications, kidney function, gallbladder history, thyroid conditions, pregnancy status, and other factors are all reviewed. A licensed clinician must determine whether any GLP-1 medication is safe and appropriate for you specifically.
What a Licensed Clinician Reviews
Medical screening for a GLP-1 medication is more than a BMI check. A licensed clinician will typically review a range of health factors before determining whether a GLP-1 medication is appropriate — and which specific medication, if any, may be suitable for your situation.
Height, Weight & BMI
Current measurements to assess eligibility threshold. BMI is a starting criterion, not a sole determinant.
Medical History
Past and current health conditions, previous weight-management treatments, and relevant diagnoses.
Current Medications
All prescription and over-the-counter medications and supplements to screen for interactions and contraindications.
Diabetes Status
Whether you have type 2 diabetes affects which medication may be indicated and how treatment goals are framed.
Cardiovascular & Metabolic Conditions
Blood pressure, cholesterol, and established cardiovascular disease history may be relevant to medication selection and monitoring.
Kidney Function
Some GLP-1 prescribing information includes kidney-related precautions. Clinicians may review kidney function or history as part of screening.
Pregnancy & Breastfeeding Status
GLP-1 medications are not recommended during pregnancy or breastfeeding. Clinicians review reproductive health status and family planning considerations.
Pancreatitis & Gallbladder History
History of pancreatitis or gallbladder disease or removal is a clinically relevant factor given precautions noted in GLP-1 prescribing information.
Thyroid History
Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2) are contraindications noted in prescribing information for semaglutide and tirzepatide products.
Insurance & Cost Considerations
While not a clinical factor, many programs discuss coverage, prior authorization, and cost access options as part of the care planning conversation.
This list reflects commonly reviewed factors based on prescribing information and general clinical practice. Individual clinicians may review additional factors. This is not a comprehensive list and does not represent any specific program's intake process.
How Online GLP-1 Screening Works
Licensed online GLP-1 programs make it possible to complete medical screening without an in-person visit, but they still require a licensed clinician to review your health information and determine whether a prescription is medically appropriate. The process typically follows these steps:
-
1
Complete a Health Intake Form
You provide your height, weight, health goals, current medications, and medical history through a secure online form. Be thorough and accurate — misrepresenting health information creates safety risks and is not appropriate.
-
2
Licensed Clinician Reviews Your Information
A licensed clinician — not an automated system — reviews your intake, assesses eligibility based on the specific medication's approved criteria, and screens for contraindications. This step requires professional clinical judgment and takes time.
-
3
Labs May Be Required
Some programs require lab work (such as metabolic panels or HbA1c) before a clinician can complete the evaluation. Others may proceed with self-reported information initially. Requirements vary by program and patient history.
-
4
Clinician Determination
If the clinician determines a GLP-1 medication is medically appropriate, they write a valid prescription. If not, they may recommend alternative options or additional evaluation. Not every applicant will receive a prescription — medical appropriateness must be established.
-
5
Prescription Filled at a Licensed Pharmacy
Approved prescriptions are filled by a licensed pharmacy. Ongoing monitoring and follow-up check-ins are typically part of the program structure. Medication options and program structures vary by provider.
Searching "How to Qualify for Ozempic"?
Many people searching for GLP-1 eligibility use the term "Ozempic" as a shorthand for all GLP-1 medications — but Ozempic has a specific FDA-approved indication that matters significantly for understanding eligibility.
Ozempic Is Not FDA-Approved for Weight Loss
Ozempic (semaglutide, up to 2 mg weekly) is FDA-approved for improving glycemic control in adults with type 2 diabetes, not as a standalone weight-loss medication. Its eligibility criteria relate to type 2 diabetes diagnosis and management goals — not BMI thresholds for weight management.
Wegovy — a different semaglutide formulation approved at 2.4 mg — is the FDA-approved brand for chronic weight management. Similarly, Zepbound (tirzepatide) is FDA-approved for weight management, while Mounjaro (same active ingredient) is approved for type 2 diabetes. These are not the same medications for eligibility purposes.
If your goal is weight management without a type 2 diabetes diagnosis, Wegovy or Zepbound are the FDA-approved options to discuss with a licensed clinician. Some clinicians may prescribe Ozempic off-label for weight management — whether that is appropriate for your situation is an individual clinical decision that this page cannot advise on.
Explore your options: Wegovy online prescription · Zepbound online prescription · Ozempic information · Semaglutide guide · Tirzepatide guide
Insurance, Prior Authorization, and HSA/FSA: Separate from Medical Eligibility
Medical eligibility (what a clinician determines) and insurance coverage (what your plan pays for) are two entirely separate questions. You may be medically eligible for a GLP-1 medication and still face coverage barriers — or vice versa.
Key Points About GLP-1 Coverage and Access
- Insurance coverage varies widely: Some plans cover Wegovy or Zepbound for weight management; others exclude them entirely or require prior authorization with supporting documentation.
- Prior authorization criteria vary: Requirements differ by insurer, plan type, employer benefits design, state Medicaid policy, and specific medication. Your prescriber can often assist with the prior authorization process if coverage is available.
- Type 2 diabetes drugs differ: Ozempic and Mounjaro tend to have broader diabetes-related coverage in many plans, but coverage still depends on your specific plan and clinical documentation.
- No coverage does not end your options: Some programs offer self-pay pricing, manufacturer savings programs, or access through compounding pharmacies — each with important distinctions and caveats worth understanding before proceeding.
- HSA/FSA eligibility: Prescription GLP-1 medications with a valid prescription may qualify as reimbursable medical expenses under HSA or FSA accounts. Consult your plan administrator or a tax professional — this page does not provide tax or benefits advice.
For detailed information on medication costs, prior authorization support, and coverage considerations, see our GLP-1 cost guide and insurance coverage page.
What If You Don't Qualify?
Not everyone who completes a medical screening will receive a GLP-1 prescription. That is the expected and appropriate outcome of a legitimate medical process — and it exists to protect patients from inappropriate treatment.
Do not misrepresent your health information. Providing false information about your BMI, symptoms, diabetes status, or medical history to obtain a prescription creates serious safety risks and may constitute fraud. Legitimate programs require accurate information to make sound clinical decisions.
If a clinician says you don't qualify: Ask about other evidence-based weight management options, lifestyle support programs, or what health factors might change your eligibility over time. Weight management is a complex medical area with multiple clinical pathways — GLP-1 medications are one option, not the only one.
Avoid workarounds. Seeking GLP-1 medications without a valid prescription, using unverified compounded preparations, or purchasing products marketed as GLP-1 alternatives bypasses the medical oversight that protects you from harm. The FDA has raised significant concerns about these products and their risks.
Topics to Discuss with a Licensed Clinician
Before or during a GLP-1 eligibility evaluation, consider bringing up these topics for a more complete medical review. Thorough, honest information helps a licensed clinician make the most appropriate determination for your situation.
- Your current height, weight, and any recent changes in weight
- All prescription and over-the-counter medications and supplements
- Any history of type 2 diabetes, prediabetes, or other metabolic conditions
- History of pancreatitis, gallbladder disease, or gallbladder removal
- Personal or family history of thyroid cancer (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2)
- Kidney health, blood pressure, and cardiovascular history
- Pregnancy status, breastfeeding, or family planning considerations
- Insurance coverage, prior authorization needs, and cost or access questions
- Previous weight-management treatments or medications you have tried
- Any current symptoms or concerns if already using a GLP-1 medication
For a full overview of GLP-1 safety considerations and what to watch for during treatment, see our GLP-1 safety guide and side effects page.
Explore the GLP-1 Medications Guide
Compare Licensed Online GLP-1 Programs
Licensed online GLP-1 programs connect you with a clinician who will review your medical history, assess whether a GLP-1 medication is appropriate for your situation, and — if it is — write a valid prescription through a legitimate pharmacy. Medical screening and clinician approval are required; these programs do not offer guaranteed prescriptions or bypass medical review.
Prescription required. Medical screening and clinician review required. Not all applicants will receive a prescription. Affiliate disclosure: this site may earn a referral fee from programs listed.
Sources
The following official sources were used for prescribing information and FDA guidance referenced on this page. Verify against the most current version of each document.
-
FDA — FDA Approves New Medication for Chronic Weight Management (Zepbound/tirzepatide)
https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management -
Zepbound (tirzepatide) — US Prescribing Information (FDA Access Data, 2026)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s042lbl.pdf -
Wegovy (semaglutide) — US Prescribing Information (FDA Access Data, 2026)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s033lbl.pdf -
Ozempic (semaglutide) — Official Product Page (Novo Nordisk)
https://www.ozempic.com/ -
FDA — Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss -
IRS Publication 502 — Medical and Dental Expenses (general HSA/FSA reference; not tax advice)
https://www.irs.gov/publications/p502